Posted by Michael Wonder on 08 Oct 2023
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease after two or more lines of systemic therapy
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of belumosudil in the NHS in England.
For the time being, belumosudil mesylate is not recommended for the treatment of patients 12 years and over with chronic graft versus host disease after two or more systemic treatments.
